Latest Headlines

  1. SYNAPS Dx Brings El Paso, Texas Marketplace First Highly Accurate Diagnostic Alzheimer’s Disease Test For Patients Diagnosed With Dementia 3/8/2023

    SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer’s disease (AD), is pleased to announce that the Advanced Neurology, Epilepsy and Sleep Centers (ANESC) with locations in the El Paso, Texas area will be among the first in the country to offer area residents access to DISCERN, a minimally invasive diagnostic test.

  2. Researchers From Rowan University And Durin Technologies Announce Highly Accurate Blood Test For Alzheimer's Disease 3/8/2023

    A team of researchers from Rowan-Virtua School of Osteopathic Medicine (Rowan-Virtua SOM) and Durin Technologies, Inc., have announced the results of a newly-designed blood test that can detect the presence of Alzheimer's disease-related pathology up to 10 years before symptoms arise with a nearly 97 percent accuracy rate.

  3. Spectrum Solutions Acquires Alimetrix, Inc. And Microarrays, Inc. To Expand Laboratory Products And Testing Capabilities 3/7/2023

    Spectrum Solutions today announced the acquisitions of Alimetrix, Inc., a CLIA and CAP accredited molecular diagnostic laboratory skilled at custom qualitative and quantitative assay development, and Microarrays, Inc., a leader in customer array-based products that are used as biological research tools – gene expression arrays, reverse and forward phase protein arrays.

  4. Abbott Receives FDA Clearance For First Commercially Available Lab-Based Blood Test To Help Evaluate Concussion 3/7/2023

    Abbott (NYSE: ABT) has received U.S. Food and Drug Administration clearance for what will be the first commercially available laboratory traumatic brain injury (TBI) blood test, making it widely available to hospitals in the United States.

  5. VieCure And Exact Sciences Enter Strategic Collaboration Aimed At Improving Patient Access To Genomic Testing 3/6/2023

    VieCure, a cancer care company with a market-leading artificial intelligence, informatics, and clinical decision support platform, announced today a strategic collaboration with Exact Sciences, a leading provider of cancer screening and diagnostic tests, to improve access to precision oncology diagnostics for patients and community oncologists within the United States.

  6. Ibex And Alverno Laboratories Sign Multi-Year, Multi-Tissue Expansion Agreement Of AI For Cancer Diagnosis 3/6/2023

    Alverno Laboratories, a provider of high-quality diagnostic testing services and one of the largest integrated laboratory networks in the United States, and Ibex Medical Analytics, the leader in AI-powered cancer diagnostics, today announced a new agreement to expand the deployment of Ibex's Galen™ suite of Artificial Intelligence (AI) solutions to the entire Alverno network across Illinois and Indiana.

  7. Alpha Tau Announces Grant Of Expanded Radioactive License And Final Pre-Clinical Laboratory Regulatory Approval At Its Jerusalem Headquarters 3/3/2023

    Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that the Israeli Ministry of Environmental Protection has granted the Company an amended radioactive license in the main manufacturing floor of its production facility in Jerusalem, increasing the maximum allowable amount of Thorium-228 for use and possession to produce Alpha DaRT sources from 30 milliCurie to 100 milliCurie.

  8. Vector Laboratories Acquires Click Chemistry Tools And Fluoroprobes To Expand Manufacturing Capabilities 3/2/2023

    Vector Laboratories, the pioneer of innovative proteomic and glycomic research solutions, today announced the acquisitions of Click Chemistry Tools, a manufacturer of click chemistry linkers and labeling reagents, and Fluoroprobes, a leader in fluorescent probes and dyes.

  9. Children’s Hospital Los Angeles Develops Liquid Biopsy Test For Pediatric Solid Tumors 3/2/2023

    Pediatric solid tumors make up approximately 40% of all childhood cancers. While pediatric cancer is rare, children can develop a wide range of tumor types, located in different parts of the body,

  10. Biocartis Group NV: Biocartis Announces The US FDA 510(k) Clearance For The Idylla™ MSI Test 3/2/2023

    Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the U.S. Food and Drug Administration (FDA) 510(k) clearance1 for its fully automated Idylla™ MSI Test.